Speaking of the new agreement, Derma Sciences' CEO Ed Quilty stated, "This is an important milestone for us. Group purchasing agreements such as this one will open up vast new selling opportunities for our growing sales team. MedAssets is a prominent group purchasing organization and we are pleased they decided to enter into an agreement with Derma for our proprietary product. We look forward to educating their customers on the benefits of MEDIHONEY."
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large-scale randomized controlled studies on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.
MedAssets (Nasdaq: MDAS) partners with healthcare providers to improve
their financial strength by implementing integrated spend management and
revenue cycle solutions that help control cost, improve margins and cash
flow, increase regulatory compliance, and optimize operational efficiency.
MedAssets serves more than 125 health systems, 2,500 hospitals and 30,000
non- acute ca
|SOURCE Derma Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved